Literature DB >> 11466405

Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells.

I Motta1, F André, A Lim, J Tartaglia, W I Cox, L Zitvogel, E Angevin, P Kourilsky.   

Abstract

We have investigated the possible usefulness of recombinant canarypox virus (ALVAC) encoding the melanoma-associated Ag, Melan-A/MART-1 (MART-1), in cancer immunotherapy, using a dendritic cell (DC)-based approach. ALVAC MART-1-infected DC express, and are able to process and present, the Ag coded by the viral vector. One consistent feature of infection by ALVAC is that these viruses induce apoptosis, and we show cross-presentation of Ag when uninfected DC are cocultured with ALVAC MART-1-infected DC. Uptake of apoptotic virally infected DC by uninfected DC and subsequent expression of tumor Ag in the latter were verified by flow cytometry analysis, image cytometry, and confocal microscopy. Functional activity was monitored in vitro by the stimulation of a MART-1-specific cytotoxic T cell clone. Heightened efficiency in Ag presentation is evidenced in the 2- to 3-fold increase in IFN-gamma production by the T cell clone, as compared with the ALVAC-infected DC alone. Cocultures of ALVAC MART-1-infected and uninfected DC are able to induce MART-1-specific T cell immune responses, as assessed by HLA class I/peptide tetramer binding, IFN-gamma ELISPOT assays, and cytotoxicity tests. Overall, our data indicate that DC infected with recombinant canarypox viruses may represent an efficient presentation platform for tumor Ags, which can be exploited in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466405     DOI: 10.4049/jimmunol.167.3.1795

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy.

Authors:  Laila Samady; Emanuela Costigliola; Luci MacCormac; Yvonne McGrath; Steve Cleverley; Caroline E Lilley; Jill Smith; David S Latchman; Benny Chain; Robert S Coffin
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming.

Authors:  Stefan Freigang; Denise Egger; Kurt Bienz; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

Review 3.  Cross-presentation: dendritic cells and macrophages bite off more than they can chew!

Authors:  Sven Brode; Paul A Macary
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

Review 4.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

5.  Immunogenicity of cytopathic and noncytopathic viral vectors.

Authors:  Gabriela Plesa; Philip M McKenna; Matthias J Schnell; Laurence C Eisenlohr
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 6.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

7.  The genome of canarypox virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; G F Kutish; D L Rock
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.

Authors:  Beatriz Perdiguero; Carmen Elena Gómez; Jose Luis Nájera; Carlos Oscar S Sorzano; Julie Delaloye; Rubén González-Sanz; Victoria Jiménez; Thierry Roger; Thierry Calandra; Giuseppe Pantaleo; Mariano Esteban
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

9.  Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity.

Authors:  Jing-Yue Yang; Xiao Li; Li Gao; Zeng-Hui Teng; Wen-Chao Liu
Journal:  Exp Ther Med       Date:  2012-07-06       Impact factor: 2.447

10.  Trial watch: Peptide vaccines in cancer therapy.

Authors:  Erika Vacchelli; Isabelle Martins; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.